FCF Fox Corporate Finance GmbH is pleasedto publishthe new“FCF Healthcare & Life Sciences Venture Capital Monitor – USA08/2026.”
The FCF Healthcare & Life Sciences Venture Capital Monitor – USA is a monthly overview of financing trends in the venture capital sector, with a focus on U.S. healthcare and life sciences companies.
As of the end of August 2026, we have identified the following current VC trends in the United States:
Total Healthcare & Life Sciences funding reached EUR 26,262m (+4% vs. 2025)
Biotech/Pharma received 43% of the total investment volume (EUR 11,235m), with oncology being the leading indication (30%)
In August, Sail Biomedicines secured the highest transaction volume with EUR 529m, followed by LifeMine with EUR 164m and Cityblock with EUR 101m
Boston Scientific (United States) is the most active investor (by deal volume in 2026), followed by General Catalyst (United States) and Jonson & Johnson JJDC (United States)
